Spring Issue of GIST Cancer Journal has Arrived
The Life Raft Group is pleased to announce the release of the ninth issue of The GIST Cancer Journal, the official journal of the Life Raft Group. The journal is intended to serve as [...]
GIST: Actualizacion en el tratamiento
"GIST: Actualizacion en el tratamiento", presentación del Matias Chacon, May 12, 2016.
GIST Keep Swimming: Words to Live By
Life with cancer is like tossing all your dreams, goals and achievements into a bag, shaking it up and dumping it onto the floor to be stomped upon. Some say I was lucky to get my diagnosis at age 16, before I had a career or a family to support.
Leading GIST Experts Weigh in at ESMO
David Josephy On behalf of The Life Raft Group USA and Life Raft Group Canada, I attended the Sarcoma & GIST 2016 meeting organized by the European Society for Medical Oncology (ESMO) [...]
Brief from ASCO’s Clinical Cancer Advances 2016
On February 4, 2016, Life Raft Group member Noha Hussein attended the American Society of Clinical Oncology’s (ASCO) Capitol Hill Briefing on their report, “Clinical Cancer Advances 2016,” in Washington, DC at the Rayburn [...]
Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]
Proton Pump Inhibitors Linked to Kidney Disease
A recent study published in the JAMA Internal Medicine reports a link between the use of proton pump inhibitors (PPIs) and an increased risk of kidney disease. More research is warranted to show PPIs [...]
LRG Supports New Jersey Legislation to Limit Patient Cost Sharing
Although GIST is among the few rare diseases that has oral chemotherapy drug treatment options available to its patients, the cost of affording these life saving medications can sometimes impose deep financial hardship depending [...]
GIST Collaborative Tissue Bank: A researcher’s perspective
The Life Raft Group GIST Collaborative Tissue Bank consists of a collection of tumor specimens from a large number of patients, stored at Stanford University. The advantages of having a tissue bank for a [...]
Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.